Triple

Target class: NMDA receptor antagonist
Context triple: [Memantine, instanceOf, NMDA receptor antagonist]

• A. cannabinoid receptor
  A cannabinoid receptor is a cell-surface G protein–coupled receptor that binds endogenous, plant-derived, or synthetic cannabinoids to modulate processes such as pain perception, appetite, mood, and immune function.
• B. neuraminidase inhibitor
  A neuraminidase inhibitor is an antiviral drug that blocks the activity of the viral neuraminidase enzyme, preventing the release and spread of influenza viruses from infected cells.
• C. Alzheimer’s disease drug chosen
  An Alzheimer’s disease drug is a pharmacological agent designed to prevent, slow, or alleviate the cognitive and functional decline associated with Alzheimer’s pathology, typically by targeting amyloid, tau, neurotransmitter systems, or related neurodegenerative mechanisms.
• D. G protein–coupled receptor
  A G protein–coupled receptor is a membrane-spanning protein that detects extracellular signals and activates intracellular G proteins to trigger specific cellular responses.
• E. disease-modifying therapy
  A disease-modifying therapy is a treatment that alters the underlying course or mechanisms of a disease to slow its progression, reduce long-term damage, or change its overall outcome rather than just alleviating symptoms.
• F. None of above.